{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:17:30Z","timestamp":1785521850435,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13760-025-02984-9","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T04:48:38Z","timestamp":1769748518000},"page":"989-997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exit strategy patterns in second-line therapies for relapsing forms of multiple sclerosis"],"prefix":"10.1007","volume":"126","author":[{"given":"Ali","family":"Rezaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Rezaeimanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosar","family":"Kohandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareh","family":"Shahmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Jahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirreza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdorreza","family":"Naser Moghadasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"12","key":"2984_CR1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40263-022-00965-7","volume":"36","author":"L Freeman","year":"2022","unstructured":"Freeman L, Longbrake EE, Coyle PK, Hendin B, Vollmer T (2022) High-Efficacy therapies for Treatment-Na\u00efve individuals with Relapsing-Remitting multiple sclerosis. CNS Drugs 36(12):1285\u20131299","journal-title":"CNS Drugs"},{"issue":"10","key":"2984_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M et al (2021) Treatment escalation vs immediate initiation of highly effective treatment for patients with Relapsing-Remitting multiple sclerosis: data from 2 different National strategies. JAMA Neurol 78(10):1197\u20131204","journal-title":"JAMA Neurol"},{"issue":"6","key":"2984_CR3","doi-asserted-by":"publisher","first-page":"102826","DOI":"10.1016\/j.autrev.2021.102826","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Liao Q, Wen H, Zhang Y (2021) Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis. Autoimmun Rev 20(6):102826","journal-title":"Autoimmun Rev"},{"issue":"12","key":"2984_CR4","doi-asserted-by":"publisher","first-page":"e0144538","DOI":"10.1371\/journal.pone.0144538","volume":"10","author":"G Tsivgoulis","year":"2015","unstructured":"Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P et al (2015) The effect of disease modifying therapies on disease progression in patients with Relapsing-Remitting multiple sclerosis: A systematic review and Meta-Analysis. PLoS ONE 10(12):e0144538","journal-title":"PLoS ONE"},{"issue":"9","key":"2984_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/14740338.2020.1805430","volume":"19","author":"D Jakimovski","year":"2020","unstructured":"Jakimovski D, Vaughn CB, Eckert S, Zivadinov R, Weinstock-Guttman B (2020) Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf 19(9):1121\u20131142","journal-title":"Expert Opin Drug Saf"},{"key":"2984_CR6","doi-asserted-by":"publisher","first-page":"1243589","DOI":"10.3389\/fneur.2023.1243589","volume":"14","author":"JJ Marriott","year":"2023","unstructured":"Marriott JJ, Ekuma O, Fransoo R, Marrie RA (2023) Switching to second line MS disease-modifying therapies is associated with decreased relapse rate. Front Neurol 14:1243589","journal-title":"Front Neurol"},{"issue":"8","key":"2984_CR7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/ene.13936","volume":"26","author":"M Boremalm","year":"2019","unstructured":"Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A et al (2019) Natalizumab, rituximab and Fingolimod as escalation therapy in multiple sclerosis. Eur J Neurol 26(8):1060\u20131067","journal-title":"Eur J Neurol"},{"issue":"3","key":"2984_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s00415-023-12137-8","volume":"271","author":"P Iaffaldano","year":"2024","unstructured":"Iaffaldano P, Lucisano G, Guerra T, Patti F, Cocco E, De Luca G et al (2024) Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS registry. J Neurol 271(3):1150\u20131159","journal-title":"J Neurol"},{"issue":"8","key":"2984_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s12325-024-02902-0","volume":"41","author":"M Gudesblatt","year":"2024","unstructured":"Gudesblatt M, Bumstead B, Buhse M, Zarif M, Morrow SA, Nicholas JA et al (2024) De-escalation of Disease-Modifying therapy for people with multiple sclerosis due to safety considerations: characterizing 1-Year outcomes in 25 people who switched from Ocrelizumab to diroximel fumarate. Adv Therapy 41(8):3059\u20133075","journal-title":"Adv Therapy"},{"key":"2984_CR10","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.msard.2020.102124","volume":"42","author":"F Patti","year":"2020","unstructured":"Patti F, Chisari CG, D\u2019Amico E, Annovazzi P, Banfi P, Bergamaschi R et al (2020) Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Mult Scler Relat Disord 42:102124","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"2984_CR11","doi-asserted-by":"publisher","first-page":"e0267346","DOI":"10.1371\/journal.pone.0267346","volume":"17","author":"T Biernacki","year":"2022","unstructured":"Biernacki T, Sandi D, F\u00fcvesi J, Fricska-Nagy Z, Kincses TZ, \u00c1cs P et al (2022) The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. PLoS ONE 17(4):e0267346","journal-title":"PLoS ONE"},{"issue":"3","key":"2984_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01616412.2020.1722913","volume":"42","author":"MK Boziki","year":"2020","unstructured":"Boziki MK, Karapanayotides T, Papadopoulos G, Lagoudaki R, Melo P, Bakirtzis C et al (2020) Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk. Neurol Res 42(3):209\u2013221","journal-title":"Neurol Res"},{"issue":"2","key":"2984_CR13","doi-asserted-by":"publisher","first-page":"e2036321","DOI":"10.1001\/jamanetworkopen.2020.36321","volume":"4","author":"CL McAtee","year":"2021","unstructured":"McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M et al (2021) Association of rituximab use with adverse events in Children, Adolescents, and young adults. JAMA Netw Open 4(2):e2036321","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2984_CR14","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00415-021-10950-7","volume":"269","author":"K Bigaut","year":"2022","unstructured":"Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M et al (2022) Ocrelizumab versus Fingolimod after natalizumab cessation in multiple sclerosis: an observational study. J Neurol 269(6):3295\u20133300","journal-title":"J Neurol"},{"issue":"2","key":"2984_CR15","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s13311-021-01037-2","volume":"18","author":"A Zangh\u00ec","year":"2021","unstructured":"Zangh\u00ec A, Gallo A, Avolio C, Capuano R, Lucchini M, Petracca M et al (2021) Exit strategies in Natalizumab-Treated RRMS at high risk of progressive multifocal leukoencephalopathy: a multicentre comparison study. Neurotherapeutics 18(2):1166\u20131174","journal-title":"Neurotherapeutics"},{"issue":"7","key":"2984_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","volume":"80","author":"C Zhu","year":"2023","unstructured":"Zhu C, Kalincik T, Horakova D, Zhou Z, Buzzard K, Skibina O et al (2023) Comparison between dimethyl Fumarate, Fingolimod, and Ocrelizumab after natalizumab cessation. JAMA Neurol 80(7):739\u2013748","journal-title":"JAMA Neurol"},{"key":"2984_CR17","doi-asserted-by":"publisher","first-page":"104564","DOI":"10.1016\/j.msard.2023.104564","volume":"71","author":"AU Fakih","year":"2023","unstructured":"Fakih AU, Sahraian MA, Paybast S, Naser Moghadasi A (2023) Effectiveness and safety of switching from Fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis. Mult Scler Relat Disord 71:104564","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"2984_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","volume":"75","author":"M Granqvist","year":"2018","unstructured":"Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T et al (2018) Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol 75(3):320\u2013327","journal-title":"JAMA Neurol"},{"key":"2984_CR19","doi-asserted-by":"publisher","first-page":"117957352412627","DOI":"10.1177\/11795735241262743","volume":"16","author":"P Potuznik","year":"2024","unstructured":"Potuznik P, Drahota J, Horakova D, Peterka M, Mazouchova A, Matyas D et al (2024) Real-world effectiveness of cladribine as an escalation strategy for MS: insights from the Czech nationwide remus registry. J Cent Nerv Syst Dis 16:11795735241262743","journal-title":"J Cent Nerv Syst Dis"},{"key":"2984_CR20","doi-asserted-by":"publisher","first-page":"104491","DOI":"10.1016\/j.msard.2022.104491","volume":"70","author":"PS Sorensen","year":"2023","unstructured":"Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Sch\u00e4fer J et al (2023) Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. Mult Scler Relat Disord 70:104491","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"2984_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/13524585221137502","volume":"29","author":"T Spelman","year":"2023","unstructured":"Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G et al (2023) Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry. Mult Scler 29(2):221\u2013235","journal-title":"Mult Scler"},{"key":"2984_CR22","doi-asserted-by":"publisher","first-page":"175628642413042","DOI":"10.1177\/17562864241304212","volume":"18","author":"A Zangh\u00ec","year":"2025","unstructured":"Zangh\u00ec A, Fantozzi R, Foschi M, Signoriello E, Inglese M, Lus G et al (2025) Identifying cladribine prescription pattern in MS: an Italian multicentre study. Ther Adv Neurol Disord 18:17562864241304212","journal-title":"Ther Adv Neurol Disord"},{"issue":"12","key":"2984_CR23","first-page":"1330","volume":"93","author":"C Zhu","year":"2022","unstructured":"Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S et al (2022) Comparing switch to ocrelizumab, cladribine or natalizumab after Fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry 93(12):1330\u20131337","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"2984_CR24","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s10072-023-06608-z","volume":"44","author":"C Boz","year":"2023","unstructured":"Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R et al (2023) The comparative effectiveness of fingolimod, natalizumab, and Ocrelizumab in relapsing-remitting multiple sclerosis. Neurol Sci 44(6):2121\u20132129","journal-title":"Neurol Sci"},{"issue":"2","key":"2984_CR25","first-page":"205521732110155","volume":"7","author":"MG Sotiropoulos","year":"2021","unstructured":"Sotiropoulos MG, Lokhande H, Healy BC, Polgar-Turcsanyi M, Glanz BI, Bakshi R et al (2021) Relapse recovery in multiple sclerosis: effect of treatment and contribution to long-term disability. Mult Scler J Exp Transl Clin 7(2):20552173211015503","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"2984_CR26","doi-asserted-by":"publisher","first-page":"11584","DOI":"10.1038\/s41598-023-38415-z","volume":"13","author":"V Fuh-Ngwa","year":"2023","unstructured":"Fuh-Ngwa V, Charlesworth JC, Zhou Y, van der Mei I, Melton PE, Broadley SA et al (2023) The association between disability progression, relapses, and treatment in early relapse onset MS: an observational, multi-centre, longitudinal cohort study. Sci Rep 13(1):11584","journal-title":"Sci Rep"},{"issue":"9","key":"2984_CR27","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, Ocampo A, Hatami F, \u010cuklina J et al (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147\u20133161","journal-title":"Brain"},{"issue":"1","key":"2984_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP (2024) Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 271(1):105\u2013115","journal-title":"J Neurol"},{"key":"2984_CR29","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.msard.2025.106507","volume":"100","author":"F Ladeira","year":"2025","unstructured":"Ladeira F, Soares M, Faustino P, Leal Rato M, Gomes I, Caetano A et al (2025) Multiple sclerosis relapse incomplete recovery and associated factors \u2013 a systematic review and meta-analysis. Multiple Scler Relat Disorders 100:106507","journal-title":"Multiple Scler Relat Disorders"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02984-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-025-02984-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-025-02984-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:07:21Z","timestamp":1785517641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-025-02984-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1007\/s13760-025-02984-9","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amirreza Azimi, Abdorreza Naser Moghadasi and Mohammad Ali Sahraian have received educational, research grants, lecture honorarium, travel supports to attend scientific meetings from Biogen-Idec, Merck-Serono, Cinnagen, Zistdaru, Zahravi and Genzyme.Other authors have no conflict of interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}